Oxidized Clopidogrel Solid Preparation for Stable Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in formulating a stable solid preparation of (7aS, 2'S)-2-oxo-clopidogrel that is bioequivalent to commercially available clopidogrel bisulfate tablets, due to its low solubility, high permeability, instability under certain conditions, and individual variability in metabolism, leading to clopidogrel resistance and ineffective anticoagulant effects.
Innovation Solution
A solid preparation comprising (7aS, 2'S)-2-oxo-clopidogrel with a specific ratio of disintegrant to binder (1:20) and optimized excipient composition, including fillers like pre-gelatinized starch and lactose, disintegrants like low-substituted hydroxypropyl cellulose, and lubricants like sodium stearyl fumarate, ensuring stable and continuous drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If (7aS, 2'S)-2-oxo-clopidogrel is formulated as an ordinary tablet, then the drug can be administered orally, but the preparation has poor stability due to the drug's instability under high temperature, acid and alkali conditions
Solution Approach 1:
The patent uses a composite formulation containing (7aS, 2'S)-2-oxo-clopidogrel combined with specific excipients including disintegrants (cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose), binders (hydroxypropyl methyl cellulose, hydroxypropyl cellulose), fillers (lactose, pre-gelatinized starch), and lubricants (sodium stearyl fumarate, magnesium stearate). This composite material approach creates a stable solid preparation that maintains drug stability while enabling oral administration.
2Speed
If the disintegrant amount is increased to improve drug release, then the dissolution rate increases, but the preparation stability decreases
Solution Approach 1:
The patent optimizes the disintegrant to binder mass ratio to specific ranges (1-20:1, preferably 2.5-15:1, more preferably 3-5:1) to achieve the desired dissolution rate while maintaining preparation stability. This parameter optimization balances the competing requirements of rapid drug release and formulation stability.
3Reliability
If clopidogrel is administered to overcome resistance, then the anticoagulant effect can be achieved, but individual differences in metabolism cause variable efficacy
Solution Approach 1:
The patent provides (7aS, 2'S)-2-oxo-clopidogrel, which is the active intermediate metabolite already formed in the liver metabolism pathway. By administering this metabolite directly, the patent bypasses the variable CYP enzyme metabolism step that causes clopidogrel resistance and individual variability, ensuring reliable anticoagulant effect regardless of patient metabolic differences.
4Strength
If the binder amount is increased to improve tablet strength, then the mechanical strength increases, but the dissolution rate decreases
Solution Approach 1:
The patent controls the binder content within specific ranges (1.0-6.0 wt%, preferably 3.0-5.0 wt%) and optimizes the disintegrant to binder mass ratio to achieve the desired balance between tablet mechanical strength and dissolution rate. This parameter control ensures adequate tablet strength while maintaining rapid drug release.
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention provides a solid preparation containing (7aS,2'S)-2-oxo-clopidogrel and a preparation method therefor. The solid preparation is an oral tablet containing (7aS,2'S)-2-oxo-clopidogrel and pharmaceutically acceptable excipients, the excipients comprising a filler, a disintegrant, a binder, and a lubricant.